Ifosfamide- and paclitaxel-based treatment of relapsed and refractory lymphoma.

Abstract

Several trials of new salvage therapies for relapsed and refractory non-Hodgkin's lymphoma are based on ifosfamide and paclitaxel. These programs variably Induce clinical remissions and prepare patients for stem cell and bone marrow transplantations. Ifosfamide-containing regimens are also being evaluated in the treatment of newly diagnosed patients. However, no data exist with regard to paclitaxel-containing regimens outside salvage settings. This report reviews the effects of these compounds in the treatment of relapsed and refractory non-Hodgkin's lymphoma and proposes likely directions for future study.